Menu
Search
|

Menu

Close
X

Perrigo Company PLC PRGO.N (New York Stock Exchange)

60.43 USD
-2.36 (-3.76%)
As of Nov 20
chart
Previous Close 62.79
Open 62.50
Volume 644,384
3m Avg Volume 316,651
Today’s High 63.10
Today’s Low 60.38
52 Week High 95.82
52 Week Low 60.38
Shares Outstanding (mil) 142.61
Market Capitalization (mil) 12,381.50
Forward P/E --
Dividend (Yield %) 0.16 ( 0.74 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.80 Mean rating from 15 analysts

KEY STATS

Revenue (mm, USD)
FY18
3,536
FY17
4,946
FY16
5,281
FY15
5,049
EPS (USD)
FY18
0.341
FY17
0.950
FY16
-27.988
FY15
1.885
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
2.46
5.69
Price to Book (MRQ)
vs sector
2.04
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
60.43
15.71
LT Debt to Equity (MRQ)
vs sector
53.74
11.53
Return on Investment (TTM)
vs sector
-22.33
15.05
Return on Equity (TTM)
vs sector
-38.96
16.62

EXECUTIVE LEADERSHIP

Marry Brlas
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Murray Kessler
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Ronald Winowiecki
Chief Financial Officer, Since 2018
Salary: $479,137.00
Bonus: $509,444.00
James Michaud
Chief Human Resource Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
Thomas Farrington
Executive Vice President, Chief Information Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Treasury Building
Grand Canal Street Lower
DUBLIN     L2 2

Phone:

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. The CHC segment is focused on the sale of OTC store brand products. The BCH segment develops, manufactures, markets and distributes various European OTC brands. The Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs. The Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri.

SPONSORED STORIES